Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma

被引：10
|
作者：
Yoshida, Masahiro [1 ]
Nakaya, Yosuke [1 ]
Shimizu, Katsujun [1 ]
Tatsumi, Naoko [1 ]
Tsutsumi, Minako [1 ]
Fuseya, Hoyuri [1 ]
Horiuchi, Mirei [1 ]
Yoshimura, Takuro [1 ]
Hayashi, Yoshiki [1 ]
Nakao, Takafumi [1 ]
Inoue, Takeshi [2 ]
Yamane, Takahisa [1 ]
机构：
[1] Osaka City Gen Hosp, Dept Hematol, Osaka, Japan
[2] Osaka City Gen Hosp, Dept Pathol, Osaka, Japan
来源：
SCIENTIFIC REPORTS | 2021年 / 11卷 / 01期
关键词：
D O I：
10.1038/s41598-021-82615-4
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Treatment of patients with malignancy sometimes be delayed due to various reasons. Several studies revealed that an influence of diagnosis-to-treatment interval (DTI) on outcomes differs depending on the type of malignancy. In this study, we evaluated the influence of DTI on clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). A total of 199 patients were identified with a median DTI of 22 days. At 2 years, patients with short DTI (0-22 days) showed significantly poorer OS (62.7% vs 86.4%) and PFS (55.1% vs 75.9%) compared to those with long DTI (over 22 days). Although short DTI was strongly correlated with several known adverse factors, it remained to be an independent prognostic factor by multivariate analysis. In conclusion, our study confirmed the importance of DTI in patients with DLBCL. Researchers should consider DTI as one of the important prognostic factors and plan clinical trials to be able to enroll patients with aggressive disease requiring urgent treatment.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Impact of the Diagnosis-to-Treatment Interval (DTI) on Outcomes in Older Adults with Diffuse Large B-Cell Lymphoma (DLBCL) Treated in the Real-World Setting
    Hamlin, Paul A.
    Torka, Pallawi
    Hansen, Eric
    Belli, Andrew J.
    Ambrose, Jacob
    Zettler, Christina M.
    Fernandes, Laura L.
    Wiley, Stephanie
    Perry, Brittney
    Wang, Ching-Kun
    BLOOD, 2024, 144 : 5101 - 5102
  • [22] Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma
    Epperla, Narendranath
    Switchenko, Jeffrey
    Bachanova, Veronika
    Gerson, James N.
    Barta, Stefan K.
    Gordon, Max J.
    Danilov, Alexey, V
    Grover, Natalie S.
    Mathews, Stephanie
    Burkart, Madelyn
    Karmali, Reem
    Sawalha, Yazeed
    Hill, Brian T.
    Ghosh, Nilanjan
    Park, Steven I.
    Bond, David A.
    Hamadani, Mehdi
    Fenske, Timothy S.
    Martin, Peter
    Malecek, Mary-Kate
    Kahl, Brad S.
    Flowers, Christopher R.
    Link, Brian K.
    Kaplan, Lawrence D.
    Inwards, David J.
    Feldman, Andrew L.
    Hsi, Eric D.
    Maddocks, Kami
    Blum, Kristie A.
    Bartlett, Nancy L.
    Cerhan, James R.
    Leonard, John P.
    Habermann, Thomas M.
    Maurer, Matthew J.
    Cohen, Jonathon B.
    BLOOD ADVANCES, 2023, 7 (11) : 2287 - 2296
  • [23] Diagnosis and treatment in patients with B-cell lymphoma unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt's lymphoma
    Baryakh, E. A.
    Misyurina, A. E.
    Kovrigina, A. M.
    Obukhova, T. N.
    Gemdzhyan, E. G.
    Vorobyev, V. I.
    Mangasarova, Ya. K.
    Polyakov, Yu. Yu.
    Magomedova, A. U.
    Klyasova, G. A.
    Misyurin, V. A.
    Yatsyk, G. A.
    Shevelev, A. A.
    Kostina, I. E.
    Vorobyev, A. I.
    Kravchenko, S. K.
    TERAPEVTICHESKII ARKHIV, 2015, 87 (08) : 77 - 85
  • [24] Prognostic Significance of Circulating Lymphoma Cells in Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
    Muringampurath-John, Disni
    Flowers, Christopher R.
    Jabbar, Adrian A.
    Sinha, Rajni
    Arellano, Martha
    Bernal-Mizrachi, Leon
    Kaufman, Jonathan L.
    Jaye, David L.
    Chen, Zhengjia
    Lechowicz, Mary Jo
    Lonial, Sagar
    Armitage, James O.
    Khoury, H. Jean
    BLOOD, 2009, 114 (22) : 1151 - 1152
  • [25] Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma
    Wang, Yucai
    Maurer, Matthew J.
    Larson, Melissa C.
    Allmer, Cristine
    Feldman, Andrew L.
    Bennani, N. Nora
    Thompson, Carrie A.
    Porrata, Luis F.
    Habermann, Thomas M.
    Witzig, Thomas E.
    Ansell, Stephen M.
    Slager, Susan L.
    Nowakowski, Grzegorz S.
    Cerhan, James R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (06) : 820 - 828
  • [26] Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma
    Wang, Yucai
    Link, Brian K.
    Witzig, Thomas E.
    Maurer, Matthew J.
    Allmer, Cristine
    King, Rebecca L.
    Feldman, Andrew L.
    Habermann, Thomas M.
    Ansell, Stephen M.
    Slager, Susan L.
    Cerhan, James R.
    Nowakowski, Grzegorz S.
    BLOOD, 2019, 134 (16) : 1289 - 1297
  • [27] Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma
    Pirosa, Maria Cristina
    Stathis, Anastasios
    Zucca, Emanuele
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [28] Treatment strategies for patients with diffuse large B-cell lymphoma
    Poletto, Stefano
    Novo, Mattia
    Paruzzo, Luca
    Frascione, Pio Manlio Mirko
    Vitolo, Umberto
    CANCER TREATMENT REVIEWS, 2022, 110
  • [29] Treatment of elderly patients with diffuse large B-cell lymphoma
    Nösslinger T.
    memo - Magazine of European Medical Oncology, 2016, 9 (1) : 8 - 12
  • [30] Clinical, Hematological, Genetic, and Pathological Significance in Newly Diagnosed High Grade B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma
    Qu, Qingyuan
    Zhang, Lingyan
    Xue, Chao
    Ge, Xueling
    Lv, Xiao
    Lu, Kang
    Wang, Xin
    Jiang, Yujie
    BLOOD, 2019, 134
12345